Generic Drugs Industry Announces Earnings Results, Leadership Appointments, and Conference Participation - Analyst Notes on Mylan, Zoetis, Hospira, Horizon Pharma and The Medicines Co

NEW YORK, April 30, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Mylan, Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS), Hospira Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP) and The Medicines Co. (NASDAQ: MDCO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1816-100free.

--
Mylan, Inc. Analyst Notes
On April 25, 2014, Mylan, Inc. (Mylan) announced that the Company has filed suit against the US Food and Drug Administration (FDA), challenging the agency's decision regarding generic drug marketing exclusivity on Celecoxib Capsules -the generic version of Pfizer's Celebrex. According to Mylan, FDA has seriously erred in its decision in this case, and maintains that it is in a position to receive final approval on May 30, 2014, upon expiration of Celebrex's remaining patents. Mylan's CEO, Heather Bresch said, "We believe the FDA has made an unprecedented error in this case which clearly caught all industry participants off guard, as evidenced by some who have already settled with Pfizer for December 2014 launch dates, which is post patent expiry. Mylan seeks an order compelling FDA to grant final approval of Mylan's ANDA on May 30, 2014." The full analyst notes on Mylan are available to download free of charge at:

http://www.analystsreview.com/1816-MYL-30Apr2014.pdf

--
Zoetis Inc. Analyst Notes
On April 22, 2014, Zoetis Inc. (Zoetis) has named Glenn David, Senior Vice President of Finance Operations as acting CFO, and he will assume responsibility for the oversight of the Company's financial management and global operations, effective immediately. According to Zoetis, David will succeed Executive Vice President and CFO, Richard Passov, who will be leaving the Company at the end of April 2014. The Company also said that with more than 20 years of experience in finance and operations - including roles at Pfizer, Bankers Trust, Paine Webber and Credit Suisse, David has played a key role in leading the financial operations for Zoetis since its Initial Public Offering. The full analyst notes on Zoetis are available to download free of charge at:

http://www.analystsreview.com/1816-ZTS-30Apr2014.pdf

--
Hospira Inc. Analyst Notes
On April 22, 2014, Hospira Inc. (Hospira) announced that it will present at three conferences in the month of May 2014. Hospira will be present at: The Bank of America Merrill Lynch 2014 Health Care Conference at Las Vegas on May 14, 2014 at 10:00 a.m. PT; UBS Global Healthcare Conference on May 20, 2014 at 11:30 a.m. ET; and Sanford C. Bernstein's 30th Annual Strategic Decisions Conference at 8:00 a.m. ET on May 29, 2014 at New York. Hospira also informed that the presentations will be available through a live audiocast via the investor relations section of the Company's website, wherein a replay will also be available for 30 days after the conclusion of the respective events. The full analyst notes on Hospira are available to download free of charge at:

http://www.analystsreview.com/1816-HSP-30Apr2014.pdf

--
Horizon Pharma, Inc. Analyst Notes
On April 25, 2014, Horizon Pharma, Inc. (Horizon) has scheduled to release its Q1 2014 financial results on May 9, 2014 before market opening. Horizon stated that on the same day following the announcement, its management will host a live conference call and webcast at 8:00 am ET to review the Company's financial and operating results and provide a general business update. The live webcast of the call and its replay will be accessible via Horizon's website. The full analyst notes on Horizon Pharma are available to download free of charge at:

http://www.analystsreview.com/1816-HZNP-30Apr2014.pdf

--
The Medicines Co. Analyst Notes
On April 23, 2014, The Medicines Co. reported its financial results for Q1 2014. Net revenue increased 13.8% YoY to $177.2 million. Net loss was $5.0 million or $0.08 per diluted share, compared to net loss of $11.6 million or $0.21 per diluted share in Q1 2013. For the quarter, revenues from Angiomax® (bivalirudin)/Angiox® (bivalirudin) increased 9.0% YoY to $155.7 million driven by U.S. growth; Recothrom® Thrombin topical (recombinant) revenue in the U.S. up 57.0% YoY to $13.5 million. "The first quarter was a strong start to the year for us with continued revenue growth. We remain focused on the progression of our late stage portfolio through regulatory filings, reimbursement processes, and manufacturing to execute on the six product launches anticipated in the next 18 months," remarked Glenn Sblendorio, President and CFO. The full analyst notes on The Medicines Co are available to download free of charge at:

http://www.analystsreview.com/1816-MDCO-30Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review